scutellarin has been researched along with Osteosarcoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, G; Jian, M; Li, X; Liu, Z; Song, F; Sun, X; Wang, Z; Zhang, H | 1 |
Li, H; Liu, Y; Wang, Z; Yan, J | 1 |
Han, J; Huang, Y; Li, X; Wang, P; Xia, X; Zhang, H; Zhang, L; Zhao, W | 1 |
1 review(s) available for scutellarin and Osteosarcoma
Article | Year |
---|---|
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
Topics: Animals; Antineoplastic Agents; Biological Products; Bone Neoplasms; Matrix Metalloproteinase 13; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Molecular Docking Simulation; Osteosarcoma; Peptides | 2022 |
2 other study(ies) available for scutellarin and Osteosarcoma
Article | Year |
---|---|
Flavonoid compound breviscapine suppresses human osteosarcoma Saos-2 progression property and induces apoptosis by regulating mitochondria-dependent pathway.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Flavonoids; Humans; Mitochondria; Neoplasm Proteins; Osteosarcoma; Signal Transduction | 2021 |
EGR1 promoted anticancer effects of Scutellarin via regulating LINC00857/miR-150-5p/c-Myc in osteosarcoma.
Topics: Antineoplastic Agents; Apigenin; Carcinogenesis; Cell Line, Tumor; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Glucuronates; Humans; MicroRNAs; Osteosarcoma; RNA, Long Noncoding | 2021 |